IP Library Granted Patent US 8,193,363
Granted Patent B2
US 8,193,363 · App. 12/544,556 · Granted Jun 5, 2012

Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits

Assignee: AstraZeneca AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,193,363
App. No.
12/544,556
Granted
Jun 5, 2012
Kind
B2
Abstract

The present invention relates to novel derivatives that are suitable as precursors to compounds that are useful for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. The compounds deriving from these precursors are useful in methods of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease by positron emission tomography (PET) as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. Furthermore, the present invention also discloses the precursor compounds in crystalline form.

Claims (5)

1. A compound or salt thereof, wherein the compound is [5-(5-ethoxymethoxy-benzofuran-2-yl)-6-nitro-pyridin-2-yl]-methyl-carbamic acid tert-butyl ester.

2. The compound or salt thereof according to claim 1 , wherein the compound or salt is in crystalline form.

3. The compound or salt thereof according to claim 2 , wherein the crystalline form exhibits at least one endothermic event with onset between 70° C. and 300° C.

4. The compound or salt thereof according to claim 2 , wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising at least one specific diffraction peak at about 2-theta=6.18°.

5. The compound or salt thereof according to claim 2 , wherein the crystalline form exhibits the following diffraction peaks: 6.18, 9.14, 11.67, 14.98, and 16.44° 2-theta.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Mar 9, 2017
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: NAVIDEA BIOPHARMACEUTICALS, INC.
Reel/Frame 041518/0749 →
RELEASE OF SECURITY INTEREST Recorded Dec 24, 2015
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: NAVIDEA BIOPHARMACEUTICALS, INC.
Reel/Frame 037357/0256 →
SECURITY INTEREST Recorded May 15, 2015
From: NAVIDEA BIOPHARMACEUTICALS, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 035653/0441 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2009
From: BJORK, SETH; JOHNSTROM, PETER; NILSSON, NILS ANDERS; RUDA, KATINKA; SCHOU, PER MAGNUS; SWAHN, BRITT-MARIE; DELISSER, VERN
To: ASTRAZENECA AB
Reel/Frame 023325/0674 →
Continuity (2)
Provisional Application 61092851 · Aug 29, 2008
Related Publication 20100056796A1 · Mar 4, 2010